Streetbeat News

OPTHF

Optimi Health Corp

https://optimihealth.ca/

Industry

Pharmaceutical Preparation Manufacturing

Open

0.13

Mkt cap

12M

Volume

13K

High

0.13

P/E Ratio

-2.40

52-wk high

0.38

Low

0.12

Div yield

N/A

52-wk low

0.10

Optimi Health Corp. has announced key updates including regulatory milestones, clinical trial progress, and expanded market access, particularly highlighting the expansion of MDMA exports to Australia.

Portfolio Pulse from

March 12, 2025 | 11:45 am

Optimi Health Corp. has completed its largest batch of MDMA capsules, producing over 4,000 GMP capsules for PTSD treatment in Australia, Israel, and Canada. The company has also validated a one-year shelf life for its MDMA capsules, enhancing their usability for clinical applications.

Portfolio Pulse from

January 29, 2025 | 12:45 pm

Optimi Health Corp. has completed its non-brokered private placement, raising a total of $934,000. The company specializes in psychedelics pharmaceuticals and has distributed 1,316,668 units at $0.30 per unit in the final tranche.

Portfolio Pulse from

January 29, 2025 | 2:15 am

Optimi Health Corp. has successfully dosed the first patients in a landmark study using its natural psilocybin extract in New Zealand. The study aims to address methamphetamine addiction through indigenous frameworks.

Portfolio Pulse from

January 13, 2025 | 12:45 pm

Optimi Health Corp. has completed its second shipment of GMP-certified MDMA capsules to Australia and has increased its 2025 production forecast to support over 5,000 patients globally.

Portfolio Pulse from

January 06, 2025 | 12:45 pm

Psyence Biomedical Ltd. (NASDAQ:PBM) is advancing its psychedelic-based mental health solutions with a Phase IIb trial in Australia and the acquisition of Clairvoyant. The company is also partnering with Optimi Health (OTC:OPTHF) for psilocybin supply, aiming for significant data readouts in 2025.

Portfolio Pulse from Juan Spínelli

September 16, 2024 | 5:42 pm

Optimi Health Corp. (OTC:OPTHF) has received a license to export psilocybin and MDMA to Australia, marking a significant milestone in the medical psychedelic drugs market. The company aims to become a key player in the manufacture of pharmaceutical-grade psychedelics. Despite regulatory challenges in the U.S., Optimi is positioning itself for global market leadership.

Portfolio Pulse from Rolando García

June 06, 2024 | 1:12 am

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

Optimi Health Corp. (OTCQX:OPTHF), a Canadian psychedelics pharmaceutical manufacturer, has entered into an agreement to supply natural psilocybin to New Zealand's Mātai Medical Research Institute for the Tū Wairua Project. This marks Optimi's first supply deal in New Zealand, contributing to its global expansion. The company will provide GMP Full Spectrum Natural Psilocybin extract for a pilot study aimed at evaluating psychedelic-assisted therapy for Māori patients. The study, set for mid-2024, will integrate Māori cultural practices and aims to inform future trials for methamphetamine use disorder among Māori patients.

Portfolio Pulse from Lara Goldstein

April 09, 2024 | 7:26 pm

PharmAla Biotech (MDXXF) and Numinus Wellness (NUMIF) have entered into a sales agreement for MDMA supply for clinical trials in Canada. Similarly, Optimi Health (OPTHF) has partnered with Tel Aviv University for MDMA research on addiction. These deals mark significant advancements in MDMA-assisted psychotherapy and addiction research, with potential impacts on mental health treatment practices.

Portfolio Pulse from Lara Goldstein

March 26, 2024 | 7:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.